**Supplementary Table 4.** The AEs in different regimens

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AEs  (n/N)**＆** | DCV/ASV  %, (95% CI) | PrOD ± RBV  %, (95% CI) | EBR/GZR  %,(95% CI) | SOF/LDV±RBV  %, (95% CI) | SOF/RBV  %, (95% CI） | SOF/DCV±RBV  %, (95% CI) | GLE/PIB  %, (95% CI) | SOF/VEL±RBV  %, (95% CI) |
| Any AEs  (2,208/14,547) | 11.9, (10.6-13.3) | 22.8, (20.5-25.1) | 10.9, (8.7-13.3) | 10.0,  (9.1-10.9) | 22.6, (21.1-24.3) | 34.0,  (29.0-39.3) | 23.1, (20.7-25.8) | 7.9,  (6.6-9.4) |
| AEs | | | | | | | | |
| Fatigue  (787/14,229) | 2.6,  (2.0-3.4) | 8.0,  (6.6-9.6) | 5.7,  (4.0-7.7) | 4.2,  (3.7-4.9) | 7.2  (6.2-8.2) | 15.5,  (11.9-19.9) | 11.8, (9.8-14.1) | 2.1,  (1.4-2.9) |
| Nausea  (215/14,240) | 0.9,  (0.6-1.4) | 2.3,  (1.5-3.2) | 1.6,  (0.8-2.8) | 0.7,  (0.5-1.0) | 2.0,  (1.5-2.6) | 4.7,  (2.7-7.5) | 2.8,  (1.9-4.1) | 1.3,  (0.8-2.0) |
| Pruritus (391/14,226) | 0.9,  (0.6-1.4) | 9.4,  (7.9-11.2) | 1.6,  (0.8-2.8) | 0.9,  (0.6-1.2) | 2.9,  (2.3-3.6) | 3.8,  (2.0-6.4) | 9.2,  (7.4-11.3) | 0.9,  (0.5-1.5) |
| Headache (258/14,112) | 0.9,  (0.6-1.4) | 0.7,  (0.3-1.4) | 1.6,  (0.7-2.6) | 2.2,  (1.8-2.7) | 1.6,  (1.2-2.2) | 5.0,  (2.9-7.9) | 3.5,  (2.4-4.8) | 1.3,  (0.8-2.0) |
| Insomnia (271/14,232) | 0.9,  (0.6-1.4) | 6.9,  (5.6-8.4) | 1.3,  (0.6-2.4) | 1.0,  (0.7-1.3) | 1.7,  (1.3-2.3) | 7.6,  (5.0-11.0) | 2.1,  (1.3-3.2) | 0.7,  (0.3-1.3) |
| Vomiting  (4/10,034) | 0,  (0-0.2)\* | 0,  (0-0.4)\* | 0,  (0-0.5)\* | 0.1,  (0-0.2) | 0.1,  (0-0.3) | 0,  (0-1.4)\* | 0,  (0-0.3)\* | 0.06,  (0-0.3) |
| Hypertensive  (5/10,038) | 0.2,  (0-0.6) | 0,  (0-0.4)\* | 0.1,  (0-0.8) | 0,  (0-0.1)\* | 0,  (0-0.2)\* | 0,  (0-1.4)\* | 0.1,  (0-0.5) | 0,  (0-0.2)\* |
| Depression  (13/10,039) | 0.2, (0-0.6) | 0.1,  (0-0.7) | 0,  (0-0.5)\* | 0,  (0-0.1)\* | 0,  (0-0.5) | 0,  (0-1.4)\* | 0.5,  (0.1-1.2) | 0,  (0-0.2)\* |
| Jaundice  (7/10,038) | 0,  (0-0.2)\* | 0.5,  (0.1-1.3) | 0.1,  (0-0.8) | 0,  (0-0.1)\* | 0,  (0-0.2)\* | 0,  (0-1.4)\* | 0,  (0-0.3)\* | 0.1,  (0-0.3) |
| Treatment discontinuation  (319/14,629) | 6.4,  (5.4-7.4) | 3.2,  (2.3-4.2) | 1.3,  (0.6-2.3) | 0.9,  (0.6-1.2) | 1.3,  (0.9-1.8) | 0.5,  (0-1.9) | 2.2,  (1.3-3.1) | 0.9,  (0.5-1.5) |
| Deaths  (125/14,326) | 1.1,  (0.7-1.6) | 0.7,  (0.4-1.3) | 0.6,  (0.2-1.4) | 0.9,  (0.6-1.2) | 0.5,  (0.3-0.9) | 1.5,  (0.5-3.6) | 0.5,  (0.2-1.2) | 1.0,  (0.3-2.2) |

\*one-sided, 97.5% confidence interval. **＆**(n/N): Number of adverse events/number of assessable patients. AEs, Adverse events; SOF, Sofosbuvir; VEL, Velpatasvir; RBV, Ribavirin; DCV, Daclatasvir; ASV, Asunaprevir; LDV, Ledipasvir; PrOD, Paritaprevir/ritonavir, ombitasvir + dasabuvir; EBR, Elbasvir; GZR, Grazoprevir; GLE, Glecaprevir; PIB, Pibrentasvir; CI, Confidence interval.